Skip to main content

What the FDA labels say about taking them together

Nelfinavir and trabectedin

Trabectedin's FDA label (Yondelis) of January 6, 2026 names nelfinavir in its drug interactions section; the nelfinavir label PlainMeds reads does not name trabectedin. The trabectedin label: “Avoid using strong CYP3A inhibitors in patients taking YONDELIS.”

Check it at the source: the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON); the trabectedin FDA label on DailyMed (effective June 29, 2026, Apotex Corp.).

What does the nelfinavir label say about trabectedin?

Nelfinavir's label (effective December 11, 2025) does not name trabectedin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed

What does the trabectedin label say about nelfinavir?

Yondelis label (Janssen Products, LP, January 6, 2026), drug interactions

Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, indinavir, lopinavir, ritonavir, boceprevir, nelfinavir, saquinavir, telaprevir, nefazodone, conivaptan) in patients taking YONDELIS.

Source: FDA drug label (Yondelis, NDA207953), Janssen Products, LP, effective January 6, 2026 (SPL set 472bd78e-be17-4b9d-90f4-9482c3aec9ff), via openFDA

Source: FDA drug label (EVDI), Apotex Corp., effective June 29, 2026 (SPL set c1d50f5c-4202-27f3-4798-a9708114ddea), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Nelfinavir generic labelers
0Trabectedin generic labelers
NelfinavirTrabectedin
Labeled forHIVn/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?